BOSTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first-in-class ...
Key abstracts for GS-6207 presented at CROI 2020 include: Poster 3691: Dose-Response Relationship of Subcutaneous Long-Acting HIV Capsid Inhibitor GS-6207 This randomized, double-blind Phase 1b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results